• Subscribe
  • Magazine
  • Past Issues
  • Surveys
  • Industry Statistics
  • About Us
  • Members Only
  • Best Places to Work
    • Recent Quotes
    My Watchlist
    Indicators
    PennEnergy Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Organon & Co. (NY: OGN )

    20.11 -0.20 (-0.98%)
    Official Closing Price Updated: 7:00 PM EDT, Jul 5, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 1,887,381
    Open 20.25
    Bid (Size) 20.00 (50)
    Ask (Size) 21.00 (5)
    Prev. Close 20.31
    Today's Range 19.94 - 20.31
    52wk Range 10.84 - 24.08
    Shares Outstanding N/A
    Dividend Yield 5.57%
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    3 High-Yield Dividend ETFs to Buy to Generate Passive Income
    These exchange-traded funds should keep the income flowing in regularly. 
    Via The Motley Fool
    Topics ETFs
    High Dividend 50: Organon & Co.
    Organon & Co.’s current annual dividend is $1.12 per share. At around $20 per share, Organon stock has a high yield of 5.4%. 
    Via Talk Markets

    Performance

    YTD
    +36.71%
    +36.71%
    1 Month
    -4.06%
    -4.06%
    3 Month
    +12.60%
    +12.60%
    6 Month
    +39.56%
    +39.56%
    1 Year
    +0.95%
    +0.95%

    More News

    Read More
    Value Investing Is Back! 3 Stocks With Strong Fundamentals to Buy Now
    Via InvestorPlace
    3 Stocks With Mouthwatering Dividends You Can Buy Right Now
    Via The Motley Fool
    European Medicines Agency (EMA) Validates Henlius and Organon Filings for Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14
    From Organon & Co.
    Via Business Wire
    Thursday Is Your Last Chance To Buy Organon Before The Dividend Payout
    Via Benzinga
    Wall Street's Most Accurate Analysts' Views On 3 Health Care Stocks With Over 5% Dividend Yields
    Via Benzinga
    Organon Announces Pricing of $1.0 Billion Senior Notes Offering
    From Organon & Co.
    Via Business Wire
    Organon Announces Proposed $1.0 Billion Senior Notes Offering
    From Organon & Co.
    Via Business Wire
    Organon Beats On Q1, Women's Health Leads the Charge
    Via Benzinga
    OGN Stock Earnings: Organon Beats EPS, Beats Revenue for Q1 2024
    Via InvestorPlace
    Organon Reports Results for the First Quarter Ended March 31, 2024
    From Organon & Co.
    Via Business Wire
    7 Sleeper Stocks to Buy Before Wall Street Wakes Up: April 2024
    Via InvestorPlace
    3 Healthcare Stocks With the Potential to Triple Your Investment by 2026
    Via InvestorPlace
    Organon To Report First Quarter 2024 Results and Host Conference Call on May 2, 2024
    From Organon & Co.
    Via Business Wire
    Phase 3 Comparative Clinical Study of Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14 Met Primary Endpoints
    From Organon & Co.
    Via Business Wire
    Wall Street's Most Accurate Analysts' Views On 3 Health Care Stocks Delivering High-Dividend Yields
    Via Benzinga
    Turn $500 into a Fortune: 3 Top Stock Picks for March’s Million-Dollar Rally
    Via InvestorPlace
    5 Value Stocks In The Healthcare Sector
    Via Benzinga
    Drug Maker Organon Stock Scores Relative Strength Upgrade
    Via Investor's Business Daily
    Under the Radar: 3 Overlooked Stocks Ready to Dominate the Market
    Via InvestorPlace
    New York Attorney General Urges FDA Action On Widely Used Asthma Drug's Concerns Over Pediatric Safety
    Via Benzinga
    Exposures Product Safety
    Don't Overlook These Low-Risk High-Dividend Yielding Stocks
    Via Talk Markets
    Topics Stocks
    Exposures US Equities
    First Lady Jill Biden Unveils $100M In Federal Funding To Support R&D - Watch Out for These Women Health Stocks
    Via Benzinga
    Organon Announces HADLIMA™ (adalimumab-bwwd) Has Been Exclusively Selected by the US Department of Veterans Affairs (VA), Replacing HUMIRA on Its National Formulary
    From Organon & Co.
    Via Business Wire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.